Colette DeJong

List of Publications by Citations

Source: https://exaly.com/author-pdf/7426979/colette-dejong-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20 529 10 23 g-index

27 678 11.8 4.31 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
20	Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. <i>JAMA Internal Medicine</i> , 2016 , 176, 1114-1122	11.5	289
19	Variation in Quality of Urgent Health Care Provided During Commercial Virtual Visits. <i>JAMA Internal Medicine</i> , 2016 , 176, 635-42	11.5	45
18	Validation of Prediction Models for Critical Care Outcomes Using Natural Language Processing of Electronic Health Record Data. <i>JAMA Network Open</i> , 2018 , 1, e185097	10.4	41
17	Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D. <i>JAMA Cardiology</i> , 2019 , 4, 828-830	16.2	26
16	Incorporating a New Technology While Doing No Harm, Virtually. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2351-2	27.4	23
15	An Ethical Framework for Allocating Scarce Inpatient Medications for COVID-19 in the US. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 2367-2368	27.4	18
14	The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm. <i>JAMA Internal Medicine</i> , 2020 , 180, 1118-1119	11.5	16
13	Medicare Part D PlansSCoverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease. <i>JAMA Internal Medicine</i> , 2017 , 177, 585-588	11.5	15
12	Websites that offer care over the Internet: is there an access quality tradeoff?. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1287-8	27.4	14
11	Deferral of Care for Serious Non-COVID-19 Conditions: A Hidden Harm of COVID-19. <i>JAMA Internal Medicine</i> , 2021 , 181, 274	11.5	12
10	Continuing Problems With Financial Conflicts of Interest and Clinical Practice Guidelines. <i>JAMA Internal Medicine</i> , 2018 , 178, 1715	11.5	6
9	Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D. JAMA Internal Medicine, 2020 , 180, 1696-1699	11.5	5
8	Tenofovir-based PrEP for COVID-19: an untapped opportunity?. <i>Aids</i> , 2021 , 35, 1509-1511	3.5	4
7	Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007521	5.8	2
6	Shining a Light on Industry Payments to Health Care Professionals Who Are Not Physicians. <i>JAMA Internal Medicine</i> , 2019 , 179, 1432-1433	11.5	1
5	Disclosure of Article Funding and Conflicts of Interest in High-Impact Clinical Journals. <i>Journal of General Internal Medicine</i> , 2020 , 35, 1345-1347	4	
4	Trends in the Use of Angiotensin-Converting Enzyme Inhibitor and Angiotensin-II Receptor Blocker Among United States Adults From 1999[to 2018. <i>Endocrine Practice</i> , 2021 , 27, 503-504	3.2	_

LIST OF PUBLICATIONS

3	Important Distinctions Concerning Pharmaceutical Company-Sponsored Meals and Prescribing Patterns-Reply. <i>JAMA Internal Medicine</i> , 2016 , 176, 1881	11.5
2	Electrocardiographic Harbingers of Ventricular Tachycardia Arrest-A Moment of Pause. <i>JAMA Internal Medicine</i> , 2019 , 179, 249-251	11.5
1	PatientsSCompliance With Quarantine Requirements for Exposure or Potential Symptoms of COVID-19. <i>Hawaiti Journal of Health & Social Welfare</i> , 2021 , 80, 276-282	0.6